Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, Alonzo TA, Meshinchi S. Ho PA, et al. Among authors: heerema na. J Clin Oncol. 2011 Feb 20;29(6):704-11. doi: 10.1200/JCO.2010.31.9327. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189390 Free PMC article.
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S. Ho PA, et al. Among authors: heerema na. Blood. 2009 Jun 25;113(26):6558-66. doi: 10.1182/blood-2008-10-184747. Epub 2009 Mar 20. Blood. 2009. PMID: 19304957 Free PMC article.
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. Pollard JA, et al. Among authors: heerema na. Blood. 2010 Mar 25;115(12):2372-9. doi: 10.1182/blood-2009-09-241075. Epub 2010 Jan 7. Blood. 2010. PMID: 20056794 Free PMC article.
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S. Ho PA, et al. Among authors: heerema na. Blood. 2010 Aug 5;116(5):702-10. doi: 10.1182/blood-2010-02-268953. Epub 2010 Apr 22. Blood. 2010. PMID: 20413658 Free PMC article.
Clinical implications of FLT3 mutations in pediatric AML.
Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP. Meshinchi S, et al. Among authors: heerema na. Blood. 2006 Dec 1;108(12):3654-61. doi: 10.1182/blood-2006-03-009233. Epub 2006 Aug 15. Blood. 2006. PMID: 16912228 Free PMC article. Clinical Trial.
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.
Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR, Lange BJ, Woods WG, Arceci RJ, Smith FO. Barbaric D, et al. Among authors: heerema na. Blood. 2007 Mar 15;109(6):2314-21. doi: 10.1182/blood-2005-11-025536. Epub 2006 Dec 7. Blood. 2007. PMID: 17158236 Free PMC article.
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA. Lange BJ, et al. Among authors: heerema na. Blood. 2008 Feb 1;111(3):1044-53. doi: 10.1182/blood-2007-04-084293. Epub 2007 Nov 13. Blood. 2008. PMID: 18000167 Free PMC article. Clinical Trial.
Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
Johnston DL, Alonzo TA, Gerbing RB, Hirsch B, Heerema NA, Ravindranath Y, Woods WG, Lange BJ, Gamis AS, Raimondi SC. Johnston DL, et al. Among authors: heerema na. Pediatr Blood Cancer. 2013 Dec;60(12):2073-8. doi: 10.1002/pbc.24573. Epub 2013 Aug 30. Pediatr Blood Cancer. 2013. PMID: 24039149
BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. Moore AS, et al. Among authors: heerema na. Pediatr Blood Cancer. 2014 Apr;61(4):647-52. doi: 10.1002/pbc.24822. Epub 2013 Oct 11. Pediatr Blood Cancer. 2014. PMID: 24127439 Free PMC article.
357 results